

Hong Ren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4577229/publications.pdf>

Version: 2024-02-01

102
papers

3,112
citations

212478

28
h-index

214428

50
g-index

117
all docs

117
docs citations

117
times ranked

4528
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide resequencing reveals population structure and genetic diversity of Bohai Black cattle. <i>Animal Genetics</i> , 2022, 53, 133-136.	0.6	4
2	SCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGF β ² /PI3K/AKT/GSK3 β pathway. <i>Cancer Cell International</i> , 2022, 22, 1.	1.8	67
3	Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection. <i>Liver International</i> , 2022, 42, 1287-1296.	1.9	36
4	Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence. <i>Chinese Medicine</i> , 2022, 17, 23.	1.6	5
5	Normal tissue adjacent to tumor expression profile analysis developed and validated a prognostic model based on Hippo-related genes in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 3139-3152.	1.3	14
6	TaxonKit: A practical and efficient NCBI taxonomy toolkit. <i>Journal of Genetics and Genomics</i> , 2021, 48, 844-850.	1.7	140
7	Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	6
8	Identifying potential biomarkers in hepatitis B virus infection and its response to the antiviral therapy by integrated bioinformatic analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 6558-6572.	1.6	11
9	A mechanical, electrical dual autonomous self-healing multifunctional composite hydrogel. <i>Materials Today Bio</i> , 2021, 12, 100138.	2.6	9
10	A panel of urine-derived biomarkers to identify sepsis and distinguish it from systemic inflammatory response syndrome. <i>Scientific Reports</i> , 2021, 11, 20794.	1.6	3
11	Curc-mPEG454, a PEGylated curcumin derivative, as a multi-target anti-fibrotic prodrug. <i>International Immunopharmacology</i> , 2021, 101, 108166.	1.7	4
12	The Characteristics of Natural Killer Cells and T Cells Vary With the Natural History of Chronic Hepatitis B in Children. <i>Frontiers in Pediatrics</i> , 2021, 9, 736023.	0.9	1
13	Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. <i>Chinese Medical Journal</i> , 2021, 134, 2810-2817.	0.9	4
14	Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucleos(t)ide Analogue Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 719-727.e7.	2.4	72
15	48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients. <i>Annals of Hepatology</i> , 2020, 19, 329-334.	0.6	2
16	Identification of the fatty acid synthase interaction network via iTRAQ-based proteomics indicates the potential molecular mechanisms of liver cancer metastasis. <i>Cancer Cell International</i> , 2020, 20, 332.	1.8	9
17	Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2020, 222, 611-618.	1.9	50
18	Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis. <i>Hepatology International</i> , 2020, 14, 338-346.	1.9	8

#	ARTICLE	IF	CITATIONS
19	Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients. <i>Clinical and Experimental Immunology</i> , 2020, 202, 80-92.	1.1	12
20	Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis. <i>Hepatology International</i> , 2019, 13, 757-765.	1.9	32
21	On the way towards the eradication of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 3-4.	1.0	3
22	Lamivudine therapy for chronic hepatitis B in children: a meta-analysis. <i>Virology Journal</i> , 2019, 16, 88.	1.4	8
23	Identification of key genes, pathways and potential therapeutic agents for liver fibrosis using an integrated bioinformatics analysis. <i>PeerJ</i> , 2019, 7, e6645.	0.9	31
24	Immunological Features of AECHB. , 2019, , 223-314.		0
25	Roadmap to functional cure of chronic hepatitis B: An expert consensus. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1146-1155.	1.0	57
26	A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?. <i>International Journal of Infectious Diseases</i> , 2019, 83, 56-63.	1.5	4
27	Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. <i>Hepatology International</i> , 2019, 13, 260-269.	1.9	18
28	Structural characterization and in vitro antitumor activity of A polysaccharide from <i>Artemisia annua</i> L. (Huang Huahao). <i>Carbohydrate Polymers</i> , 2019, 213, 361-369.	5.1	52
29	Misclassification of chronic hepatitis B natural history phase: Insight from new ALT, AST, AKP, and GGT reference intervals in Chinese children. <i>Clinica Chimica Acta</i> , 2019, 489, 61-67.	0.5	12
30	TGFÎ²1- miR-140-5p axis mediated up-regulation of Flap Endonuclease 1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. <i>Aging</i> , 2019, 11, 5593-5612.	1.4	25
31	Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1340-1348.	1.9	46
32	Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2018, 48, E213-E221.	1.8	19
33	Curc-mPEG454, a PEGylated Curcumin Derivative, Improves Anti-inflammatory and Antioxidant Activities: a Comparative Study. <i>Inflammation</i> , 2018, 41, 579-594.	1.7	11
34	Interpretation of liver stiffness measurementâ€based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2â€year prospective study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 296-305.	1.0	35
35	Circulating PD-1hiCXCR5+CD4+ T cells are associated with a decrease in hepatitis B surface antigen levels in patients with chronic hepatitis B who are receiving peginterferon-Î± therapy. <i>Molecular Immunology</i> , 2018, 103, 270-278.	1.0	12
36	Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis. <i>Virology Journal</i> , 2018, 15, 139.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 671-680.	1.1	0
38	Recovery of circulating CD56dim NK cells and the balance of Th17/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg. <i>International Immunopharmacology</i> , 2018, 62, 59-66.	1.7	22
39	HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-10.	0.7	82
40	Large Disparity between Prevalence and Treatment Rates for Hepatitis C in Western China. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-6.	0.7	6
41	Annexin A2 promotes liver fibrosis by mediating von Willebrand factor secretion. <i>Digestive and Liver Disease</i> , 2017, 49, 780-788.	0.4	22
42	Th17/Treg imbalance and increased interleukin-21 are associated with liver injury in patients with chronic severe hepatitis B. <i>International Immunopharmacology</i> , 2017, 46, 48-55.	1.7	26
43	CSH guidelines for the diagnosis and treatment of drug-induced liver injury. <i>Hepatology International</i> , 2017, 11, 221-241.	1.9	206
44	Natural killer cell activation contributes to hepatitis B viral control in a mouse model. <i>Scientific Reports</i> , 2017, 7, 314.	1.6	13
45	The experience of management of chronic hepatitis B in China. <i>Journal of Viral Hepatitis</i> , 2017, 24, 4-5.	1.0	6
46	Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 12-20.	1.0	21
47	Comparison of error correction algorithms for Ion Torrent PGM data: application to hepatitis B virus. <i>Scientific Reports</i> , 2017, 7, 8106.	1.6	21
48	Baseline value of intrahepatic HBV DNA over cccDNA predicts patient's response to interferon therapy. <i>Scientific Reports</i> , 2017, 7, 5937.	1.6	16
49	Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1989-1996.	1.4	14
50	Liver-infiltrating CD11b ⁺ CD27 ⁺ NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. <i>Cellular and Molecular Immunology</i> , 2017, 14, 819-829.	4.8	103
51	Molecular mechanism of C-reaction protein in promoting migration and invasion of hepatocellular carcinoma cells in vitro. <i>International Journal of Oncology</i> , 2017, 50, 1289-1298.	1.4	11
52	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 297-318.	0.7	181
53	Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients. <i>Infection and Drug Resistance</i> , 2017, Volume 10, 275-281.	1.1	4
54	PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR- α /CD36 Pathway. <i>BioMed Research International</i> , 2017, 2017, 1-11.	0.9	32

#	ARTICLE	IF	CITATIONS
55	Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. <i>Infection and Drug Resistance</i> , 2017, Volume 10, 377-392.	1.1	23
56	Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0180725.	1.1	48
57	LHBs can elevate the expression of MDR1 through HIF-1 α in patients with CHB infection: a comparative proteomic study. <i>Oncotarget</i> , 2017, 8, 4549-4562.	0.8	4
58	Upgrade Combination Response Is Limited by Prolonged Nucleos(t)ide Analogue Therapy in HBeAg-positive Chronic Hepatitis B: A Real-life Study. <i>Journal of Clinical and Translational Hepatology</i> , 2017, 6, 1-7.	0.7	2
59	Transcriptome sequencing identified hub genes for hepatocellular carcinoma by weighted-gene co-expression analysis. <i>Oncotarget</i> , 2016, 7, 38487-38499.	0.8	22
60	Production of Autoantibodies in Chronic Hepatitis B Virus Infection Is Associated with the Augmented Function of Blood CXCR5+CD4+ T Cells. <i>PLoS ONE</i> , 2016, 11, e0162241.	1.1	16
61	Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. <i>PLoS ONE</i> , 2016, 11, e0155934.	1.1	34
62	Altered Immune Profiles of Natural Killer Cells in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0160171.	1.1	16
63	Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities. <i>Scandinavian Journal of Immunology</i> , 2016, 84, 182-190.	1.3	45
64	Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1253-1261.	1.9	65
65	Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. <i>Scientific Reports</i> , 2016, 6, 20310.	1.6	88
66	Genetic analysis in a patient with nine primary malignant neoplasms: A rare case of Li-Fraumeni syndrome. <i>Oncology Reports</i> , 2016, 35, 1519-1528.	1.2	3
67	Functional dichotomy of V α 2 γ 3 T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN- γ production. <i>Scientific Reports</i> , 2016, 6, 26296.	1.6	24
68	Tfh cell-mediated humoral immune response and HBsAg level can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon- α therapy. <i>Molecular Immunology</i> , 2016, 73, 37-45.	1.0	9
69	Circulating T follicular helper cells are associated with rapid virological response in chronic hepatitis C patients undergoing peginterferon therapy. <i>International Immunopharmacology</i> , 2016, 34, 235-243.	1.7	17
70	Relationship between hepatitis B virus infection and chronic kidney disease in Asian populations: a meta-analysis. <i>Renal Failure</i> , 2016, 38, 1581-1588.	0.8	9
71	HBsAg and HBeAg in the prediction of a clinical response to peginterferon α -2b therapy in Chinese HBeAg-positive patients. <i>Virology Journal</i> , 2016, 13, 180.	1.4	6
72	Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. <i>Journal of Hepatology</i> , 2016, 65, 700-710.	1.8	331

#	ARTICLE	IF	CITATIONS
73	A strong conservative tendency in HBV transcriptase (RT): a majority of natural RT mutations derived from the S gene. <i>Liver International</i> , 2016, 36, 963-970.	1.9	4
74	Hepatitis B Virus Replication in CD34+ Hematopoietic Stem Cells From Umbilical Cord Blood. <i>Medical Science Monitor</i> , 2016, 22, 1673-1681.	0.5	11
75	RED: A Java-MySQL Software for Identifying and Visualizing RNA Editing Sites Using Rule-Based and Statistical Filters. <i>PLoS ONE</i> , 2016, 11, e0150465.	1.1	16
76	Activation of intrahepatic CD4+CXCR5+ T and CD19+ B cells is associated with viral clearance in a mouse model of acute hepatitis B virus infection. <i>Oncotarget</i> , 2016, 7, 50952-50962.	0.8	5
77	Validation of a multi-omics strategy for prioritizing personalized candidate driver genes. <i>Oncotarget</i> , 2016, 7, 38440-38450.	0.8	6
78	Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B. <i>Hepatitis Monthly</i> , 2016, 16, e35357.	0.1	3
79	Leveraging a Multi-Omics Strategy for Prioritizing Personalized Candidate Mutation-Driver Genes: A Proof-of-Concept Study. <i>Scientific Reports</i> , 2015, 5, 17564.	1.6	13
80	Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. <i>Advances in Therapy</i> , 2015, 32, 727-741.	1.3	19
81	Enhanced Functions of Peripheral $\gamma\delta$ T Cells in Chronic Hepatitis B Infection during Interferon α Treatment In Vivo and In Vitro. <i>PLoS ONE</i> , 2015, 10, e0120086.	1.1	14
82	A secretomic study on human hepatocellular carcinoma multiple drug-resistant cell lines. <i>Oncology Reports</i> , 2015, 34, 1249-1260.	1.2	10
83	Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis. <i>Hepatology International</i> , 2015, 9, 543-557.	1.9	4
84	Roles of the programmed cell death 1, T cell immunoglobulin mucin-3, and cluster of differentiation 288 pathways in the low reactivity of invariant natural killer T cells after chronic hepatitis B virus infection. <i>Archives of Virology</i> , 2015, 160, 2535-2545.	0.9	11
85	Prognostic value of metastatic lymph node ratio as an additional tool to the TNM stage system in gastric cancer. <i>European Journal of Surgical Oncology</i> , 2015, 41, 927-933.	0.5	39
86	The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: A meta-analysis. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 164-173.	0.8	17
87	Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 80-92.	0.7	20
88	The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled study. <i>Hepatology</i> , 2014, 59, 1283-1292.	3.6	69
89	Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. <i>Hepatology International</i> , 2014, 8, 72-82.	1.9	11
90	Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: A randomized trial. <i>Journal of Clinical Virology</i> , 2014, 61, 509-516.	1.6	14

#	ARTICLE	IF	CITATIONS
91	Changes in glucose-6-phosphate dehydrogenase expression results in altered behavior of HBV-associated liver cancer cells. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G611-G622.	1.6	36
92	The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: A quantitative proteomic based study. <i>Journal of Proteomics</i> , 2014, 106, 99-112.	1.2	47
93	515 VIROLOGICAL BREAKTHROUGH AND GENOTYPIC RESISTANCE IN A RANDOMIZED, CONTROLLED STUDY ON TELBIVUDINE TREATMENT APPLYING ROADMAP CONCEPT IN CHB: W76 INTERIM ANALYSIS OF EFFORT STUDY. <i>Journal of Hepatology</i> , 2012, 56, S203-S204.	1.8	6
94	Enhanced Peripheral $\gamma\delta$ T Cells Cytotoxicity Potential in Patients with HBV-Associated Acute-On-Chronic Liver Failure Might Contribute to the Disease Progression. <i>Journal of Clinical Immunology</i> , 2012, 32, 877-885.	2.0	37
95	Two new hetero-spirocyclic β -lactam derivatives from marine sediment-derived fungus <i>Aspergillus sydowi</i> D2-6. <i>Archives of Pharmacal Research</i> , 2010, 33, 499-502.	2.7	31
96	Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naïve Chinese chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2010, 17, 51-58.	1.0	19
97	Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. <i>Hepatology</i> , 2008, 47, 447-454.	3.6	147
98	Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. <i>Hepatology International</i> , 2008, 2, 486-493.	1.9	25
99	Characteristics of Circulating T Cell Receptor $\gamma\delta$ T Cells from Individuals Chronically Infected with Hepatitis B Virus (HBV): An Association between $\gamma\delta 2$ Subtype and Chronic HBV Infection. <i>Journal of Infectious Diseases</i> , 2008, 198, 1643-1650.	1.9	45
100	Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. <i>Hepatology International</i> , 2007, 1, 365-372.	1.9	42
101	Selection and their antitumor activity of antisense oligonucleotides targeting messenger RNA of vascular endothelial growth factor receptor 2. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2005, 17, 161-170.	0.7	0
102	The role of hepatitis B virus γ - gene in development of primary hepatocellular carcinoma. <i>Science in China Series C: Life Sciences</i> , 2000, 43, 293-301.	1.3	0